CROI 2015 Program and Abstracts

Poster Listings

Session P-U10 Poster Session

Poster Hall

WEDNESDAY, FEBRUARY 25, 2015 Session P-V1 Poster Session

2:30 pm– 4:00 pm Pharmacokinetics, Safety, and Efficacy of ART in Children and Youth 949 Prediction of ARV Drug Clearance in Children Frantz Foissac ; Naïm Bouazza; ElodieValade; Mailys De Sousa; Floris Fauchet; Sihem Benaboud; Deborah Hirt; Stéphane Blanche; Saïk Urien; Jean-MarcTreluyer EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Paris, France, Paris, France 950 Use of Maraviroc in HIV-1-Infected Paediatric Patients in Clinical Practice Claudia Palladino 1 ; Maria Luisa Navarro Gomez 6 ; Pere Soler-Palacín 5 ; Maria Isabel Gonzalez-Tome 7 ; Santiago Jimenez de Ory 6 ; Maria Espiau 5 ; Juan Antonio León-Leal 4 ; Clàudia 1 University of Lisbon, Lisbon, Portugal; 2 National Center for Microbiology, Madrid, Spain; 3 Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain; 4 Hospital Infantil Universitario Virgen del Rocío, Seville, Spain; 5 Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6 Hospital General Universitario Gregorio Marañón, Madrid, Spain; 7 Hospital Universitario Doce de Octubre, Madrid, Spain 951 Safety and Pharmacokinetics of Elvitegravir in HIV-1 Infected Pediatric Subjects Joseph M. Custodio 1 ;Victor Musiime 2 ; Aditya Gaur 3 ; Elizabeth McFarland 4 ;Wasana Prasitsuebsai 5 ; Lize Hellstrom 6 ; XuelianWei 1 ; Rebecca Begley 1 ; Srinivasan Ramanathan 1 ; Sean R. Bennett 1 1 Gilead Sciences, Inc., Foster City, CA, US; 2 Joint Clinical Research Centre, Kampala, Uganda; 3 St. Jude Children’s Research Hospital, Memphis, TN, US; 4 University of Colorado Denver, Aurora, CO, US; 5 HIV - NAT, Bangkok, Thailand; 6 Be Part Yoluntu Centre, Cape Town, South Africa 952 Lack of Emergent Resistance in HIV-1-Infected Adolescents on Elvitegravir-Based STRs Danielle P. Porter ; Sean R. Bennett; Erin Quirk; Michael D. Miller; Kirsten L.White Gilead Sciences, Inc., Foster City, CA, US 953 Week-24 Data From a Phase 3 Clinical Trial of E/C/F/TAF in HIV-Infected Adolescents Hilda Kizito 2 ; Aditya Gaur 3 ;Wasana Prasitsuebsai 4 ; Natella Rakhmanina 5 ; Eileen Lawson 1 ; Yongwu Shao 1 ; Sean R. Bennett 1 ; Andrew Cheng 1 ; Erin Quirk 1 1 Gilead Sciences, Inc., Foster City, CA, US; 2 Joint Clinical Research Centre, Kampala, Uganda; 3 St Jude Children’s Research Hospital, Memphis, TN, US; 4 HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; 5 Children’s National Health System, Washington, DC, US 954 Efficacy and Safety of Long-Term Tenofovir DF (TDF) Therapy in HIV- Infected Children Xavier Saez-Llorens 2 ; Jaime G. Deville 3 ; Ayesha Mirza 4 ; Janet S. Chen 5 ; Aditya Gaur 6 ; Mobeen Rathore 4 ; Dana Hardin 7 ;Ya-Pei Liu 1 ; Erin Quirk 1 GS-US-104-0352 StudyTeam 1 Gilead Sciences, Inc., Foster City, CA, US; 2 Hospital del Niño, Panama City, Panama; 3 University of California Los Angeles, Los Angeles, CA, US; 4 University of Florida, Jacksonville, FL, US; 5 Drexel University College of Medicine, Philadelphia, PA, US; 6 St Jude Children’s Research Hospital, Memphis, TN, US; 7 Eli Lilly, Indianapolis, IN, US 955 Acceptability of Lopinavir/r Minitabs, Tablets and Syrups in HIV-Infected Children Adeodata Kekitiinwa CHAPAS-2 Baylor College of Medicine Children’s Foundation Uganda, Kampala, Uganda 956 Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line ART Linda Aurpibul 1 ;Wasana Prasitsuebsai 2 ;Tavitiya Sudjaritruk 3 ; Pope Kosalaraksa 4 ; Nia Kurniati 6 ; Khanh HuuTruong 5 ;Viet Chau Do 7 ; SirinyaTeeraananchai 2 ; Stephen J. Kerr 2 theTASER-Pediatrics Study Group 1 Research Institute for Health Sciences, Chaing Mai University, Chiang Mai, Thailand; 2 The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3 Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4 Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; 5 Children’s Hospital 1, Ho Chi Minh City, Viet Nam; 6 Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 7 Children’s Hospital 2, Ho Chi Minh City, Viet Nam Fortuny 3 ;Verónica Briz 2 CoRISpe working group

Poster Hall

2:30 pm– 4:00 pm Postexposure Prophylaxis (PEP) 957 Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis Surasak Wiboonchutikul 1 ;VarapornThientong 1 ; Patama Sutha 1 ; Boonchai Kowadisaiburana 2 ;Weerawat Manosuthi 1 1 Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand; 2 Bangkok Hospital, Bangkok, Thailand 958 Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis Rosalind Foster 1 ; John McAllister 2 ;Tim R. Read 3 ; Anna Pierce 4 ; Robyn Richardson 2 ; Anna McNulty 1 ; Andrew Carr 2 On behalf of the EPEP Study Researchers 1 Sydney Sexual Health Centre, Sydney, Australia; 2 St Vincent’s Centre for Applied Medical Research, Sydney, Australia; 3 Melbourne Sexual Health Centre, Melbourne, Australia; 4 The Alfred Hospital, Melbourne, Australia 959 Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials Lorna Leal ; Agathe Leon; BertaTorres; Alexy Inciarte; Constanza Lucero; Josep Mallolas; Maria Martinez-Rebollar; Ana González-Cordón; Jose M. Gatell; Felipe Garcia Hospital Clínic Barcelona, Barcelona, Spain 960 Effects of Three Regimens of PEP on the Immune System of HIV- Seronegative Individuals Alberto C. Guardo 1 ; Lorna Leal 2 ; Agathe Leon 2 ; Cristina Rodriguez de Miguel 2 ; Manel E. Bargallo 1 ; Cristina Rovira 1 ; Josep Llach 2 ; Jose M. Gatell 2 ; Felipe Garcia 2 ; Montserrat Plana 1 1 L’Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; 2 Hospital Clinic, Barcelona, Spain 961 Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learned Goli Haidari 1 ; Naomi Fitzgerald 4 ; Sonia Raffe 2 ; Nneka Nwokolo 3 ; Olamide Dosekun 1 ; Mark D. Lawton 5 ; Nickie Mackie 1 ; Julie Fox 4 ; Martin Fisher 2 ; Sarah Fidler 1 1 St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 2 Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3 Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 4 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 5 The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 6 St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 7 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 8 Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 9 St Mary’s Hospital– Imperial College Healthcare NHS Trust, London, United Kingdom 2:30 pm– 4:00 pm PrEP and Microbicide Challenge 962 FTC/TDF Prevents SHIV Infection in C trachomatis and T vaginalis -Infected Macaques Jessica Radzio ;Tara Henning; James Mitchell; Angela Holder; Debra Hanson; Janet McNicholl;Walid Heneine; John Papp; Ellen Kersh; Gerardo Garcia-Lerma US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US 963 Impact of Sexually Transmitted Infections on the Efficacy of Tenofovir Vaginal Gel in Macaques Natalia Makarova;Tara Henning; AndrewTaylor; Chuong Dinh; Carol Farshy; Janet McNicholl; THURSDAY, FEBRUARY 26, 2015 Session P-V2 Poster Session Poster Hall

Poster Listings

John Papp;Walid Heneine; Ellen Kersh; Charles W. Dobard US Centers for Disease Control and Prevention, Atlanta, GA, US

73

CROI 2015